|
1
|
Wagner JC, Sleggs CA and Marchand P:
Diffuse pleural mesothelioma and asbestos exposure in the North
Western Cape Province. Br J Ind Med. 17:260–271. 1960.PubMed/NCBI
|
|
2
|
Delgermaa V, Takahashi K, Park EK, Le GV,
Hara T and Sorahan T: Global mesothelioma deaths reported to the
World Health Organization between 1994 and 2008. Bull World Health
Organ. 89:716–724. 724A–724C. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ramazzini C: The global health dimensions
of asbestos and asbestos-related diseases. J Occup Health.
58:220–223. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Järvholm B and Burdorf A: Emerging
evidence that the ban on asbestos use is reducing the occurrence of
pleural mesothelioma in Sweden. Scand J Public Health. 43:875–881.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Price B and Ware A: Time trend of
mesothelioma incidence in the United States and projection of
future cases: An update based on SEER data for 1973 through 2005.
Crit Rev Toxicol. 39:576–588. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan E, Warren N, Darnton AJ and Hodgson
JT: Projection of mesothelioma mortality in Britain using Bayesian
methods. Br J Cancer. 103:430–436. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carbone M, Ly BH, Dodson RF, Pagano I,
Morris PT, Dogan UA, Gazdar AF, Pass HI and Yang H: Malignant
mesothelioma: Facts, myths, and hypotheses. J Cell Physiol.
227:44–58. 2012. View Article : Google Scholar
|
|
8
|
Gilham C, Rake C, Burdett G, Nicholson AG,
Davison L, Franchini A, Carpenter J, Hodgson J, Darnton A and Peto
J: Pleural mesothelioma and lung cancer risks in relation to
occupational history and asbestos lung burden. Occup Environ Med.
73:290–299. 2016. View Article : Google Scholar :
|
|
9
|
Algranti E, Saito CA, Carneiro AP, Moreira
B, Mendonça EM and Bussacos MA: The next mesothelioma wave:
Mortality trends and forecast to 2030 in Brazil. Cancer Epidemiol.
39:687–692. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baas P, Fennell D, Kerr KM, Van Schil PE,
Haas RL and Peters S; ESMO Guidelines Committee: Malignant pleural
mesothelioma: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 26(Suppl 5): v31–v39. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van Meerbeeck JP, Gaafar R, Manegold C,
Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A,
Debruyne C and Giaccone G; European Organisation for Research and
Treatment of Cancer Lung Cancer Group; National Cancer Institute of
Canada: Randomized phase III study of cisplatin with or without
raltitrexed in patients with malignant pleural mesothelioma: An
intergroup study of the European Organisation for Research and
Treatment of Cancer Lung Cancer Group and the National Cancer
Institute of Canada. J Clin Oncol. 23:6881–6889. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S,
Manegold C, et al: Phase III study of pemetrexed in combination
with cisplatin versus cisplatin alone in patients with malignant
pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baird A, Richard D, O'Byrne KJ and Gray
SG: Epigenetic Therapy in Lung Cancer and Mesothelioma. Epigenetic
Cancer Therapy. 1st. Gray SG: Academic Press; pp. 189–213. 2015,
View Article : Google Scholar
|
|
14
|
Baylin SB and Jones PA: Epigenetic
determinants of cancer. Cold Spring Harb Perspect Biol.
8:a0195052016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X, Tang N, Rishi AK, Pass HI and
Wali A: Methylation profile landscape in mesothelioma: Possible
implications in early detection, disease progression, and
therapeutic options. Methods Mol Biol. 1238:235–247. 2015.
View Article : Google Scholar
|
|
16
|
Kelly WK, O'Connor OA, Krug LM, Chiao JH,
Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP,
Schwartz L, et al: Phase I study of an oral histone deacetylase
inhibitor, suberoylanilide hydroxamic acid, in patients with
advanced cancer. J Clin Oncol. 23:3923–3931. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Krug LM, Kindler HL, Calvert H, Manegold
C, Tsao AS, Fennell D, Öhman R, Plummer R, Eberhardt WE, Fukuoka K,
et al: Vorinostat in patients with advanced malignant pleural
mesothelioma who have progressed on previous chemotherapy
(VANTAGE-014): A phase 3, double-blind, randomised,
placebo-controlled trial. Lancet Oncol. 16:447–456. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cregan S, MacDonagh L, Gao Y, Barr MP,
O'Byrne KJ, Finn SP, Cuffe S and Gray SG: KAT5 (Tip60) is a
potential therapeutic target in malignant pleural mesothelioma. Int
J Oncol. 48:1290–1296. 2016.PubMed/NCBI
|
|
19
|
Sacco JJ, Kenyani J, Butt Z, Carter R,
Chew HY, Cheeseman LP, Darling S, Denny M, Urbé S, Clague MJ, et
al: Loss of the deubiquitylase BAP1 alters class I histone
deacetylase expression and sensitivity of mesothelioma cells to
HDAC inhibitors. Oncotarget. 6:13757–13771. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bosselut R: Pleiotropic functions of
H3K27Me3 demethylases in immune cell differentiation. Trends
Immunol. 37:102–113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goto Y, Shinjo K, Kondo Y, Shen L, Toyota
M, Suzuki H, Gao W, An B, Fujii M, Murakami H, et al: Epigenetic
profiles distinguish malignant pleural mesothelioma from lung
adenocarcinoma. Cancer Res. 69:9073–9082. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Conway E, Healy E and Bracken AP: PRC2
mediated H3K27 methylations in cellular identity and cancer. Curr
Opin Cell Biol. 37:42–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kemp CD, Rao M, Xi S, Inchauste S, Mani H,
Fetsch P, Filie A, Zhang M, Hong JA, Walker RL, et al: Polycomb
repressor complex-2 is a novel target for mesothelioma therapy.
Clin Cancer Res. 18:77–90. 2012. View Article : Google Scholar
|
|
24
|
LaFave LM, Béguelin W, Koche R, Teater M,
Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T,
Konstantinoff K, et al: Loss of BAP1 function leads to
EZH2-dependent transformation. Nat Med. 21:1344–1349. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Agger K, Cloos PA, Christensen J, Pasini
D, Rose S, Rappsilber J, Issaeva I, Canaani E, Salcini AE and Helin
K: UTX and JMJD3 are histone H3K27 demethylases involved in HOX
gene regulation and development. Nature. 449:731–734. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hong S, Cho YW, Yu LR, Yu H, Veenstra TD
and Ge K: Identification of JmjC domain-containing UTX and JMJD3 as
histone H3 lysine 27 demethylases. Proc Natl Acad Sci USA.
104:18439–18444. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Perrigue PM, Najbauer J and Barciszewski
J: Histone demethylase JMJD3 at the intersection of cellular
senescence and cancer. Biochim Biophys Acta. 1865:237–244.
2016.PubMed/NCBI
|
|
28
|
Paolicchi E, Crea F, Farrar WL, Green JE
and Danesi R: Histone lysine demethylases in breast cancer. Crit
Rev Oncol Hematol. 86:97–103. 2013. View Article : Google Scholar :
|
|
29
|
Shen Y, Guo X, Wang Y, Qiu W, Chang Y,
Zhang A and Duan X: Expression and significance of histone H3K27
demethylases in renal cell carcinoma. BMC Cancer. 12:4702012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kruidenier L, Chung CW, Cheng Z, Liddle J,
Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, et
al: A selective jumonji H3K27 demethylase inhibitor modulates the
proinflammatory macrophage response. Nature. 488:404–408. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Riss TL, Moravec RA, Niles AL, Duellman S,
Benink HA, Worzella TJ and Minor L: Cell viability assays. Assay
Guidance Manual (Internet). Sittampalam GS, Coussens NP, Nelson H,
Arkin M, Auld D, Austin C, Bejcek B, Glicksman M, Inglese J,
Iversen PW, et al: Eli Lilly & Company and the National Center
for Advancing Translational Sciences; Bethesda, MD: 2004
|
|
32
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gordon GJ, Rockwell GN, Jensen RV,
Rheinwald JG, Glickman JN, Aronson JP, Pottorf BJ, Nitz MD,
Richards WG, Sugarbaker DJ, et al: Identification of novel
candidate oncogenes and tumor suppressors in malignant pleural
mesothelioma using large-scale transcriptional profiling. Am J
Pathol. 166:1827–1840. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
De Santa F, Totaro MG, Prosperini E,
Notarbartolo S, Testa G and Natoli G: The histone H3 lysine-27
demethylase Jmjd3 links inflammation to inhibition of
polycomb-mediated gene silencing. Cell. 130:1083–1094. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bononi A, Napolitano A, Pass HI, Yang H
and Carbone M: Latest developments in our understanding of the
pathogenesis of mesothelioma and the design of targeted therapies.
Expert Rev Respir Med. 9:633–654. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Comertpay S, Pastorino S, Tanji M,
Mezzapelle R, Strianese O, Napolitano A, Baumann F, Weigel T,
Friedberg J, Sugarbaker P, et al: Evaluation of clonal origin of
malignant mesothelioma. J Transl Med. 12:3012014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Arcipowski KM, Martinez CA and
Ntziachristos P: Histone demethylases in physiology and cancer: A
tale of two enzymes, JMJD3 and UTX. Curr Opin Genet Dev. 36:59–67.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lansley SM, Varano Della Vergiliana JF,
Cleaver AL, Ren SH, Segal A, Xu MY and Lee YC: A commercially
available preparation of Staphylococcus aureus bio-products
potently inhibits tumour growth in a murine model of mesothelioma.
Respirology. 19:1025–1033. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yom SS, Busch TM, Friedberg JS, Wileyto
EP, Smith D, Glatstein E and Hahn SM: Elevated serum cytokine
levels in mesothelioma patients who have undergone pleurectomy or
extrapleural pneumonectomy and adjuvant intraoperative
photo-dynamic therapy. Photochem Photobiol. 78:75–81. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Stam TC, Swaak AJ, Kruit WH, Stoter G and
Eggermont AM: Intrapleural administration of tumour necrosis
factor-alpha (TNFalpha) in patients with mesothelioma: Cytokine
patterns and acute-phase protein response. Eur J Clin Invest.
30:336–343. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nowak AK, Millward MJ, Creaney J, Francis
RJ, Dick IM, Hasani A, van der Schaaf A, Segal A, Musk AW and Byrne
MJ: A phase II study of intermittent sunitinib malate as
second-line therapy in progressive malignant pleural mesothelioma.
J Thorac Oncol. 7:1449–1456. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee DW, Gardner R, Porter DL, Louis CU,
Ahmed N, Jensen M, Grupp SA and Mackall CL: Current concepts in the
diagnosis and management of cytokine release syndrome. Blood.
124:188–195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nowak AK, Cook AM, McDonnell AM, Millward
MJ, Creaney J, Francis RJ, Hasani A, Segal A, Musk AW, Turlach BA,
et al: A phase 1b clinical trial of the CD40-activating antibody
CP-870,893 in combination with cisplatin and pemetrexed in
malignant pleural mesothelioma. Ann Oncol. 26:2483–2490.
2015.PubMed/NCBI
|
